undamentalytics Newsletter
Sign in

Aspire-lakewood Holdings, Inc. (ASBP) stock

Add to watchlist

Add holding +

NASDAQ: ASBP Nasdaq Pharmaceuticals

Aspire-lakewood Holdings, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.

Aspire-lakewood Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds11 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Net income rising while operating cash flow falls: TTM net income grew 41.6% while operating cash flow fell 147.1% — earnings and cash are telling different stories.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -7494.8%: costs exceed revenue.
  • Heavy stock-based pay. Stock pay equals 175.0% of revenue: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 2890% and a beta of 6.0 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Revenue
$0m

Aspire-lakewood Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-10.0%
  • 1 week-10.5%
  • 1 month-16.9%
  • This year+38.3%
  • 1 year-52.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$97,659
Operating margin
-7494.8%
Net margin
-11314.1%

Cash

Stock pay % of revenue
175.0%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Agreement
  5. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Aspire-lakewood Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Aspire-lakewood Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.6 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — 0 Does not apply: no positive value
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Aspire-lakewood Holdings, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2025
Share price$5.28
Market value$8m
+ Net debt (− = net cash)$286572
Enterprise value$8m
Multiples
Price / sales n/m
Price / earnings —
Price / free cash flow —
EV / EBITDA —

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Aspire-lakewood Holdings, Inc.: too few analysts cover it.

Positioning

Short interest
0.6%
of tradable shares
Days to cover
0.25
at average volume
Short interest, 1 month
−75%
to October 15, 2026
Held by institutions
5%
of shares
Held by insiders
20.1%
of shares

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
ASBP+6%+6%−99%+38%
Industry peers (median)−14%−2%+9%−14%
S&P 500+26%+25%+18%+11%
Months that ended higher
ASBP75%67%50%27%
S&P 50067%75%75%46%
Largest fall from a high during the year
ASBP−12%−12%−99%−97%
S&P 500−10%−8%−19%−9%

Worst fall since April 11, 2022: 100% from February 11, 2025 to May 7, 2026. Getting back needed a 361448% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.15 – $14.48
From 52-week high
−49.6%
vs 50-day average
−14.5%
vs 200-day average
+50.8%
Volatility (1 year)
2890%
Beta vs S&P 500
5.96

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0
Gross profit −0 −0
Operating income −19 −7
Net income −24 −11
Diluted EPS −$16.38 —
Margins
Gross margin −1.9% −25.0%
Operating margin <−999% <−999%
Net margin <−999% <−999%
Cash flow
Cash from operations −5 −7
Stock-based pay 14 0
Balance sheet
Cash 1 12
Total debt 1 0
Net debt (negative = net cash) 0 −12
Diluted shares 1m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $14m
Short-term assets $13mLonger-term assets $0m
What it owes, and who funded it · $14m
Short-term liabilities $2mLonger-term liabilities $0mShareholders' equity $12m
  • Short-term assets cover short-term liabilities $13m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $13m short-term assets against $96,527 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$7m against $9m of interest.

From Aspire-lakewood Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
858.2%
of revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated ASBP AKAN PRFX SCNX SXTP SXTC Median
Revenue, last 12 months $97659 $258075 $17000 $821315 $1m $1m $254m
Revenue growth, last 12 months — −69.2% — 540.6% 73.2% −34.6% 9.9%
Revenue growth, 3-year average — — — −58.5% 74.9% — 5.5%
Revenue growth, latest quarter — — — 449.1% 106.0% — 6.5%
Gross margin −25.0% −60.5% −311.8% 87.7% 19.4% 21.9% 60.1%
Operating margin <−999% <−999% <−999% <−999% −774.9% −625.9% −5.9%
Operating margin, 3-year average — — — <−999% <−999% −267.4% −7.4%
Net margin <−999% −467.1% <−999% <−999% −729.9% −545.2% −7.4%
Cash from operations / revenue <−999% <−999% <−999% <−999% −789.8% −353.0% 9.4%
Free-cash-flow margin — <−999% <−999% <−999% −800.6% −353.0% 8.6%
Free-cash-flow margin, 3-year average — — — <−999% — −126.6% 7.4%
Stock pay / revenue 175.0% 21.3% >999% 257.1% 37.2% 466.2% 3.7%
Change in share count — −93.4% 368.7% 2.1% — >999% 1.9%

Median of all 76 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
United States $6,153 99.2% —
Canada $30 0.5% —
United Kingdom $19 0.3% —

From Aspire-lakewood Holdings, Inc.'s 10-K filed March 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$250,676
Institutions reporting
11
Positions opened / closed
11 / 0

Top buyers and sellers, Q2 2026: 11 institutions bought and 0 sold ; the biggest buyer was Jane Street Group, LLC (+15K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jane Street Group, LLC $79,192 15K 31.6% —
Geode Capital Management, LLC $55,931 10K 22.3% —
Vanguard Capital Management LLC $55,579 10K 22.2% —
Vanguard Fiduciary Trust Co $53,833 10K 21.5% —
Crewe Advisors LLC $3,616 1K 1.4% —
Tower Research Capital LLC (TRC) $1,511 0K 0.6% —
Toronto Dominion Bank $886 0K 0.4% —
Crossingbridge Advisors, LLC $107 0K 0.0% —
Sbi Securities Co., Ltd. $11 0K 0.0% —
Barclays PLC $5 0K 0.0% —
UBS Group AG $5 0K 0.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aspire-lakewood Holdings, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Aspire-lakewood Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Aspire-lakewood Holdings, Inc. in brief

What does Aspire-lakewood Holdings, Inc. do?
Aspire-lakewood Holdings, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Aspire-lakewood Holdings, Inc.'s stock ticker?
Aspire-lakewood Holdings, Inc. trades under the ticker ASBP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Aspire-lakewood Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jane Street Group, LLC, Geode Capital Management, LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Aspire-lakewood Holdings, Inc.'s market cap?
On December 31, 2025, Aspire-lakewood Holdings, Inc.'s market capitalisation was about $7.9M and net debt of $286,572. Market figures come from third-party market data and may be delayed.
Who are Aspire-lakewood Holdings, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Aspire-lakewood Holdings, Inc. are Akanda Corp., PRF Technologies Ltd., Scienture Holdings, Inc., 60 Degrees Pharmaceuticals, Inc. and China SXT Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against Aspire-lakewood Holdings, Inc.'s.